Genzyme Reports Financial Results for the Third Quarter of 2010
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter.
Genzyme Announces Results of Phase 3 Trial of Clolar
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced results from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
Sanofi-aventis Establishes Research Collaboration with Harvard University
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard University and sanofi-aventis.
Biocon and Pfizer Enter Into Global Commercialization Agreement
- Details
- Category: Pfizer
Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro.
Roche Group posts solid sales growth in first nine months
- Details
- Category: Roche
In the first nine months of 2010 Group sales rose 2% in local currencies (-1% in Swiss francs; 3% in US dollars) to 36.1 billion Swiss francs. Excluding Tamiflu sales, which as expected were significantly lower than in the previous year, Group sales increased 6% (3% in Swiss francs, 7% in US dollars).
GSK outlines approach to delivering advances in the treatment of rare diseases
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) provided further details about the strategic focus and development priorities of the company's unit dedicated to rare diseases. Following the announcement of a new alliance with Fondazione Telethon and Fondazione San Raffaele, Marc Dunoyer, Global Head of GlaxoSmithKline Rare Diseases, outlined his ambitions for the unit and its potential to deliver significant benefits to underserved patient groups worldwide.
Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis
- Details
- Category: Novartis
Novartis announced that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Aclasta* (zoledronic acid 5 mg) in postmenopausal women with osteoporosis[1]. The study of more than 1,200 women was presented at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.
More Pharma News ...
- 21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment
- GSK increases support for WHO strategy to improve children's health
- Merck KGaA to Introduce RebiDose, the Rebif Single Use Pre-filled Pen for Treatment of Multiple Sclerosis
- Results from a national survey of Alzheimer's Disease
- Genzyme's Alemtuzumab Shows Sustained Reduction in Relapses and Disability
- Lundbeck and Genmab enter into a research collaboration
- Novartis affirms commitment to sustain efforts toward final elimination of leprosy